Avance Clinical Acquires C3 Research Associates to Expand into North America
September 6, 2022
Avance Clinical, a PE-backed Australian CRO, has acquired North American CRO partner C3 Research Associates to expand its later‑phase clinical trial capabilities and establish a US presence. Backed by private equity firm The Riverside Company, Avance will integrate C3 into its GlobalReady model and invest in growing its North American team to support biotechs transitioning from early‑phase studies in Australia/New Zealand to later phases in the US.
- Buyers
- Avance Clinical, The Riverside Company
- Targets
- C3 Research Associates
- Platforms
- Avance Clinical
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
The Riverside Company Invests in Avance Clinical
November 9, 2021
Healthcare Services
The Riverside Company has invested in Avance Clinical, a leading Australian contract research organisation (CRO), to support the company's regional and international expansion. The investment will help Avance accelerate its clinical trials business — including vaccine and gene-technology studies — with a particular focus on growth in North America and Asia.
-
Avance Clinical Acquires U.S.-Based LumaBridge
January 7, 2026
Healthcare Services
Avance Clinical, an Australian full‑service CRO, has acquired LumaBridge, a U.S.-based oncology-focused clinical research organization. The deal expands Avance's U.S. footprint and establishes LumaBridge as the foundation of Avance's global Oncology Center of Excellence, strengthening oncology clinical trial capabilities from early‑phase through later‑phase programs.
-
Catalyst Clinical Research Merges with Ce3, Inc.
August 5, 2020
Healthcare Services
Catalyst Clinical Research, a NovaQuest-backed CRO headquartered in Wilmington, North Carolina, has merged with Ce3, Inc., an early-phase oncology-focused CRO based in Clinton, Connecticut. The transaction combines Ce3's 15+ years of oncology expertise with Catalyst's broader clinical development and technology capabilities to create a next-generation oncology-focused CRO (add-on to Catalyst's NovaQuest-backed platform).
-
The Riverside Company Acquires Clinical Education Alliance from Renovus Capital Partners
December 10, 2020
Healthcare Services
The Riverside Company has signed a definitive agreement to acquire a majority stake in Clinical Education Alliance (CEA), a Virginia-based provider of live and web-based continuing medical education (CME). Renovus Capital Partners sold its majority stake but will remain a minority investor; Riverside plans to expand CEA’s therapeutic areas, end-user base and technology offering to accelerate growth.
-
Ephicacy Consulting Group Acquires Advance Research Associates
May 2, 2024
Healthcare Services
Ephicacy Consulting Group, a biometrics CRO based in Iselin, New Jersey, has acquired Advance Research Associates (ARA), a biostatistics and data management provider based in Santa Clara, California. The add-on expands Ephicacy’s clinical analytics capabilities—particularly in biostatistics and data management—to better serve pharmaceutical, biotechnology, and medical device clients; terms were not disclosed.
-
Altasciences Acquires WCCT Global
February 12, 2021
Healthcare Services
Altasciences acquired WCCT Global, an early‑stage clinical research organization (CRO) based in Southern California, expanding its West Coast clinical pharmacology capabilities and adding 180 clinical beds. The transaction, completed February 12, 2021, augments Altasciences’ Phase I/II services and expertise in specialized areas such as ethnobridging to support biopharmaceutical sponsors.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.